Navigation Links
Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
Date:11/17/2010

ce of all-cause hospitalization than patients treated with insulin (HR=0.70; CI, 0.68-0.73; P less than 0.0001), TZDs (HR=0.94; CI, 0.91-0.98; P less than 0.05) or sulfonylureas (HR=0.89; CI, 0.86-0.92; P less than 0.0001); a comparable incidence to patients treated with metformin (HR=1.02; CI, 0.99-1.06; P greater than 0.05) and a higher incidence than patients treated with Januvia (HR=1.10; CI, 1.05-1.16; P less than 0.001). The observed differences between therapies in this study may have resulted from decreased CVD risk from BYETTA, increased CVD risk with certain other diabetes medications or some combination of each of these.

About Diabetes

Diabetes affects more than 24 million people in the U.S. and an estimated 285 million adults worldwide.(i,ii)  Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv)  In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v)  Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA® (exenatide) injection

BYETTA was the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... certain mutations enable specific cells in the,retina to ... suggests deliberate,genetic manipulations might coax an injured brain ... Investigators at St.,Jude Children,s Research Hospital have ... cancer retinoblastoma, disproving a long-standing principle of,nerve growth ...
... Oct. 18 CEL-SCI CORPORATION,(Amex: CVM ) ... is a featured presenter at the International Society ... Mr. Kersten will present on the "New Realities ... p.m. (Eastern Daylight,Time). In April 2007, CEL-SCI ...
Cached Medicine Technology:St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2
(Date:8/29/2014)... San Francisco, CA (PRWEB) August 30, 2014 ... the 10 best web conference providers in the online ... Amongst the list were global leaders Webex, GotoMeeting and ... in the industry users have to determine which provider ... Essentially, web conference businesses search for compelling consumer ...
(Date:8/29/2014)... 2014 Honey Gifts, premium Vancouver adult ... now be selling purse-sized adult toys and erotic products. ... they can be carried in a woman’s purse with ... range at Honey Gifts is also leak-free and will ... rechargeable batteries are common characteristics of Honey Gifts’ portable ...
(Date:8/29/2014)... 29, 2014 Sansego is ... an interactive online community, and a range of personalized ... all the way to professional athletes. Crowie has brought ... been with him throughout the majority of his triathlon ... in the triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... Work is the recipient of a ... Drug Abuse (NIDA) at the National Institutes of Health (NIH) ... use. Additionally, the grant provides resources to create the infrastructure ... use has increased steadily since 2007 according to NIDA, as ... and more available opioid. , A primary project at ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Ethane Web ... recently launched a new service named HTML web design. ... based service. Before tailoring the service, Ethane Web Technologies ... other companies. The company has done its best efforts ... and able to deliver outstanding results to clients. ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... ... DSPanel today announced the availability of their latest ... DSPanel announced the availability of DSPanel Performance Canvas 2.2 with Planning, ... designed to be used as an accompaniment to Sharepoint 2010 and ...
... ... 140-2 Level Certification , ... (PRWEB) May 26, 2010 -- bTrade announced today that the company’s Managed ... Transfer solutions have received the Federal Information Processing Standards (FIPS) 140-2 (Level 1) validation, ...
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... ... take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle recently announced ... VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be joining VGM ...
... ... and Curcumin have demonstrated anti-tumor properties and may serve as important therapeutic agents in ... anti-cancer chemicals has been the focus of US based Biomedical Company, Millennium Bioceutics with ... ...
... used a magnetic resonance imaging (MRI) technique called continuous ... patterns in schizophrenic patients quickly and without using radiation ... edition and July printed issue of the journal ... technique that can help reduce the cost and complexity ...
Cached Medicine News:Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:bTrade Earns Stringent Government Data Security Certification 2Health News:bTrade Earns Stringent Government Data Security Certification 3Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:VGM Insurance President Passes the Baton 2Health News:Natural Chemicals Act As Cancer Killers 2Health News:Blood flows differently through the brains of schizophrenic patients 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
The Electri-Cool® II is the premier choice when it comes to localized cold therapy systems. system offers the widest variety of application-specific pads and wraps, for your convenience....
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Medicine Products: